Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Marc N. Casper sold 40,000 shares of the business’s stock in a transaction that occurred on Thursday, March 22nd. The stock was sold at an average price of $210.16, for a total transaction of $8,406,400.00. Following the completion of the transaction, the chief executive officer now directly owns 334,622 shares of the company’s stock, valued at approximately $70,324,159.52. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Shares of TMO stock traded down $2.68 during trading on Friday, hitting $204.65. 1,703,854 shares of the stock were exchanged, compared to its average volume of 1,378,125. Thermo Fisher Scientific Inc. has a 12 month low of $151.74 and a 12 month high of $226.44. The stock has a market cap of $83,301.90, a PE ratio of 36.54, a price-to-earnings-growth ratio of 1.52 and a beta of 1.15. The company has a quick ratio of 0.92, a current ratio of 1.34 and a debt-to-equity ratio of 0.74.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $2.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. The company had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $5.72 billion. During the same quarter in the prior year, the company earned $2.41 EPS. The firm’s revenue was up 22.1% on a year-over-year basis. analysts predict that Thermo Fisher Scientific Inc. will post 10.81 earnings per share for the current year.
A number of large investors have recently bought and sold shares of TMO. Veritas Asset Management LLP raised its holdings in Thermo Fisher Scientific by 44.1% during the 3rd quarter. Veritas Asset Management LLP now owns 3,503,259 shares of the medical research company’s stock valued at $662,817,000 after buying an additional 1,072,500 shares during the last quarter. Meritage Group LP bought a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $201,383,000. Viking Global Investors LP bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at $154,660,000. Investec Asset Management LTD raised its holdings in Thermo Fisher Scientific by 28.0% during the 3rd quarter. Investec Asset Management LTD now owns 2,173,381 shares of the medical research company’s stock valued at $411,204,000 after buying an additional 475,970 shares during the last quarter. Finally, Cornerstone Investment Partners LLC raised its holdings in Thermo Fisher Scientific by 89.8% during the 4th quarter. Cornerstone Investment Partners LLC now owns 802,374 shares of the medical research company’s stock valued at $152,355,000 after buying an additional 379,703 shares during the last quarter. Institutional investors own 87.63% of the company’s stock.
TMO has been the subject of a number of research reports. ValuEngine raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “sell” rating to a “hold” rating in a research note on Saturday, January 20th. Morgan Stanley boosted their price target on shares of Thermo Fisher Scientific from $223.00 to $227.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. BTIG Research initiated coverage on shares of Thermo Fisher Scientific in a research note on Friday, January 5th. They issued a “buy” rating and a $230.00 price target for the company. Finally, Evercore ISI initiated coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $220.00 price objective for the company. One analyst has rated the stock with a hold rating and seventeen have issued a buy rating to the company. Thermo Fisher Scientific currently has a consensus rating of “Buy” and an average target price of $222.29.
TRADEMARK VIOLATION WARNING: This story was published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3296569/thermo-fisher-scientific-inc-tmo-ceo-marc-n-casper-sells-40000-shares-of-stock.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.